117 related articles for article (PubMed ID: 37376877)
1. Simultaneous Delivery of Doxorubicin and EZH2-Targeting siRNA by Vortex Magnetic Nanorods Synergistically Improved Anti-Tumor Efficacy in Triple-Negative Breast Cancer.
Lu Y; Gu F; Ma Y; Li R; Luo Y; Da X; Jiang L; Li X; Liu Y
Small; 2023 Oct; 19(43):e2301307. PubMed ID: 37376877
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
3. The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.
El Ayachi I; Fatima I; Wend P; Alva-Ornelas JA; Runke S; Kuenzinger WL; Silva J; Silva W; Gray JK; Lehr S; Barch HC; Krutilina RI; White AC; Cardiff R; Yee LD; Yang L; O'Regan RM; Lowry WE; Seagroves TN; Seewaldt V; Krum SA; Miranda-Carboni GA
Cancer Res; 2019 Mar; 79(5):982-993. PubMed ID: 30563890
[TBL] [Abstract][Full Text] [Related]
4. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.
Zhang P; Xiao Z; Wang S; Zhang M; Wei Y; Hang Q; Kim J; Yao F; Rodriguez-Aguayo C; Ton BN; Lee M; Wang Y; Zhou Z; Zeng L; Hu X; Lawhon SE; Siverly AN; Su X; Li J; Xie X; Cheng X; Liu LC; Chang HW; Chiang SF; Lopez-Berestein G; Sood AK; Chen J; You MJ; Sun SC; Liang H; Huang Y; Yang X; Sun D; Sun Y; Hung MC; Ma L
Cell Rep; 2018 Apr; 23(3):823-837. PubMed ID: 29669287
[TBL] [Abstract][Full Text] [Related]
5. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
6. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of EZH2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with siRNA molecules prevents TNBC progression and restores anti-tumor responses.
Adibfar S; Masjedi A; Nazer A; Rashidi B; Karpisheh V; Izadi S; Hassannia H; Gholizadeh Navashenaq J; Mohammadi H; Hojjat-Farsangi M; Tarokhian H; Jadidi-Niaragh F
Life Sci; 2022 Nov; 309():121008. PubMed ID: 36179812
[TBL] [Abstract][Full Text] [Related]
8. The possible role of EZH2 and DNMT1 polymorphisms in sporadic triple-negative breast carcinoma in southern Chinese females.
Tao R; Chen Z; Wu P; Liu C; Peng Y; Zhao W; Hu C; Feng J
Tumour Biol; 2015 Dec; 36(12):9849-55. PubMed ID: 26162541
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA cancer susceptibility candidate 9 promotes doxorubicin‑resistant breast cancer by binding to enhancer of zeste homolog 2.
Jiang B; Li Y; Qu X; Zhu H; Tan Y; Fan Q; Jiang Y; Liao M; Wu X
Int J Mol Med; 2018 Nov; 42(5):2801-2810. PubMed ID: 30106089
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor.
Yuan ZQ; Chen WL; You BG; Liu Y; Yang SD; Li JZ; Zhu WJ; Zhou XF; Liu C; Zhang XN
J Control Release; 2017 Dec; 268():198-211. PubMed ID: 29061511
[TBL] [Abstract][Full Text] [Related]
12. Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies.
Mei H; Wu H; Yang J; Zhou B; Wang A; Hu C; Qi S; Jiang Z; Zou F; Wang B; Liu F; Chen Y; Wang W; Liu J; Liu Q
Signal Transduct Target Ther; 2023 Jan; 8(1):18. PubMed ID: 36642705
[TBL] [Abstract][Full Text] [Related]
13. Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells.
Bai J; Ma M; Cai M; Xu F; Chen J; Wang G; Shuai X; Tao K
Cell Prolif; 2014 Jun; 47(3):211-8. PubMed ID: 24738879
[TBL] [Abstract][Full Text] [Related]
14. New perspectives in triple-negative breast cancer therapy based on treatments with TGFβ1 siRNA and doxorubicin.
Ciocan-Cȃrtiţă CA; Jurj A; Raduly L; Cojocneanu R; Moldovan A; Pileczki V; Pop LA; Budişan L; Braicu C; Korban SS; Berindan-Neagoe I
Mol Cell Biochem; 2020 Dec; 475(1-2):285-299. PubMed ID: 32888160
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
16. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
[TBL] [Abstract][Full Text] [Related]
17. Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer.
Lawrence CL; Baldwin AS
PLoS One; 2016; 11(10):e0165005. PubMed ID: 27764181
[TBL] [Abstract][Full Text] [Related]
18. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
19. Targeted treatment of triple-negative-breast cancer through pH-triggered tumour associated macrophages using smart theranostic nanoformulations.
Scialla S; Hanafy MS; Wang JL; Genicio N; Costa Da Silva M; Costa M; Oliveira-Pinto S; Baltazar F; Gallo J; Cui Z; Bañobre-López M
Int J Pharm; 2023 Feb; 632():122575. PubMed ID: 36603672
[TBL] [Abstract][Full Text] [Related]
20. Functional relationship of SNP (Ala490Thr) of an epigenetic gene
Gautam N; Verma H; Choudhary S; Kaur S; Silakari O
J Genet; 2021; 100():. PubMed ID: 34825659
[No Abstract] [Full Text] [Related]
[Next] [New Search]
